Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Shahrukh Hashmi, Yasser Mohamed Khafaga, Saud Alhayli, Hazaa Al Zahrani, Syed Ahmed, Feras Al Fraih, Marwan Shaheen, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Hala Khalil, Mahmoud Aljurf, Amr Hanbali
{"title":"自体干细胞移植治疗多发性骨髓瘤在沙特阿拉伯的结果。","authors":"Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Shahrukh Hashmi, Yasser Mohamed Khafaga, Saud Alhayli, Hazaa Al Zahrani, Syed Ahmed, Feras Al Fraih, Marwan Shaheen, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Hala Khalil, Mahmoud Aljurf, Amr Hanbali","doi":"10.5144/0256-4947.2021.198","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligible patients is induction chemotherapy followed by ASCT.</p><p><strong>Objectives: </strong>Determine the demographic characteristics of MM patients and the outcomes of ASCT.</p><p><strong>Design: </strong>Retrospective.</p><p><strong>Setting: </strong>Tumor registry database of major tertiary cancer care center in Riyadh.</p><p><strong>Patients and methods: </strong>We identified patients with newly diagnosed MM who underwent ASCT from October 1997 to March 2015.</p><p><strong>Main outcome measures: </strong>The demographic characteristics of MM patients and the outcomes of ASCT in the form of response evaluation, progression-free survival (PFS) and overall survival (OS).</p><p><strong>Sample size: </strong>169 patients with newly diagnosed MM.</p><p><strong>Results: </strong>The median age at diagnosis was 51 years (range 23-69) and 100 (59.2%) were male. The most common immunoglobulin (Ig) subtype was IgG-kappa (80 patients; 47.6%). Most patients presented with advanced ISS stage III (75 patients; 47.5%). The cytogenetic analysis was documented in only 87 patients (51.4%); about half (48.3%) had normal cytogenetics by fluorescence in situ hybridization. Deletion 13 was present in 18.4% of patients. In post-induction therapy, 84 patients (50%) achieved a complete response, which increased to 78.1% (132 patients) after ASCT. The median PFS and OS post-transplantation were 30 and 202 months, respectively. Only one patient (<1%) died in the first 100 days after transplantation.</p><p><strong>Conclusions: </strong>Our transplant eligible MM patients tend to be younger with a higher OS and a low ASCT-related mortality (<1%) than is reported internationally.</p><p><strong>Limitations: </strong>Usual limitations of a retrospective analysis using registry-level data; no data on quality of life.</p><p><strong>Conflicts of interest: </strong>None.</p>","PeriodicalId":8016,"journal":{"name":"Annals of Saudi Medicine","volume":"41 4","pages":"198-205"},"PeriodicalIF":1.5000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/00/0256-4947.2021.198.PMC8380276.pdf","citationCount":"2","resultStr":"{\"title\":\"Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia.\",\"authors\":\"Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Shahrukh Hashmi, Yasser Mohamed Khafaga, Saud Alhayli, Hazaa Al Zahrani, Syed Ahmed, Feras Al Fraih, Marwan Shaheen, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Hala Khalil, Mahmoud Aljurf, Amr Hanbali\",\"doi\":\"10.5144/0256-4947.2021.198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligible patients is induction chemotherapy followed by ASCT.</p><p><strong>Objectives: </strong>Determine the demographic characteristics of MM patients and the outcomes of ASCT.</p><p><strong>Design: </strong>Retrospective.</p><p><strong>Setting: </strong>Tumor registry database of major tertiary cancer care center in Riyadh.</p><p><strong>Patients and methods: </strong>We identified patients with newly diagnosed MM who underwent ASCT from October 1997 to March 2015.</p><p><strong>Main outcome measures: </strong>The demographic characteristics of MM patients and the outcomes of ASCT in the form of response evaluation, progression-free survival (PFS) and overall survival (OS).</p><p><strong>Sample size: </strong>169 patients with newly diagnosed MM.</p><p><strong>Results: </strong>The median age at diagnosis was 51 years (range 23-69) and 100 (59.2%) were male. The most common immunoglobulin (Ig) subtype was IgG-kappa (80 patients; 47.6%). Most patients presented with advanced ISS stage III (75 patients; 47.5%). The cytogenetic analysis was documented in only 87 patients (51.4%); about half (48.3%) had normal cytogenetics by fluorescence in situ hybridization. Deletion 13 was present in 18.4% of patients. In post-induction therapy, 84 patients (50%) achieved a complete response, which increased to 78.1% (132 patients) after ASCT. The median PFS and OS post-transplantation were 30 and 202 months, respectively. Only one patient (<1%) died in the first 100 days after transplantation.</p><p><strong>Conclusions: </strong>Our transplant eligible MM patients tend to be younger with a higher OS and a low ASCT-related mortality (<1%) than is reported internationally.</p><p><strong>Limitations: </strong>Usual limitations of a retrospective analysis using registry-level data; no data on quality of life.</p><p><strong>Conflicts of interest: </strong>None.</p>\",\"PeriodicalId\":8016,\"journal\":{\"name\":\"Annals of Saudi Medicine\",\"volume\":\"41 4\",\"pages\":\"198-205\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/00/0256-4947.2021.198.PMC8380276.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Saudi Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5144/0256-4947.2021.198\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Saudi Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5144/0256-4947.2021.198","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia.
Background: In 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligible patients is induction chemotherapy followed by ASCT.
Objectives: Determine the demographic characteristics of MM patients and the outcomes of ASCT.
Design: Retrospective.
Setting: Tumor registry database of major tertiary cancer care center in Riyadh.
Patients and methods: We identified patients with newly diagnosed MM who underwent ASCT from October 1997 to March 2015.
Main outcome measures: The demographic characteristics of MM patients and the outcomes of ASCT in the form of response evaluation, progression-free survival (PFS) and overall survival (OS).
Sample size: 169 patients with newly diagnosed MM.
Results: The median age at diagnosis was 51 years (range 23-69) and 100 (59.2%) were male. The most common immunoglobulin (Ig) subtype was IgG-kappa (80 patients; 47.6%). Most patients presented with advanced ISS stage III (75 patients; 47.5%). The cytogenetic analysis was documented in only 87 patients (51.4%); about half (48.3%) had normal cytogenetics by fluorescence in situ hybridization. Deletion 13 was present in 18.4% of patients. In post-induction therapy, 84 patients (50%) achieved a complete response, which increased to 78.1% (132 patients) after ASCT. The median PFS and OS post-transplantation were 30 and 202 months, respectively. Only one patient (<1%) died in the first 100 days after transplantation.
Conclusions: Our transplant eligible MM patients tend to be younger with a higher OS and a low ASCT-related mortality (<1%) than is reported internationally.
Limitations: Usual limitations of a retrospective analysis using registry-level data; no data on quality of life.
期刊介绍：
The Annals of Saudi Medicine (ASM) is published bimonthly by King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. We publish scientific reports of clinical interest in English. All submissions are subject to peer review by the editorial board and by reviewers in appropriate specialties. The journal will consider for publication manuscripts from any part of the world, but particularly reports that would be of interest to readers in the Middle East or other parts of Asia and Africa. Please go to the Author Resource Center for additional information.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
